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Evaluation &validation of a highly multiplexed
LATE-PCR single-tube assay for M(X)DR-TB
M. de Vos1,∗, J. Rice2, L. Rice2, B. Kreishwirth3, N.
Kurepina3, E.M. Streicher1, R.M. Warren1, P.D.
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Background: In 2006, the World Health Organization (WHO)
and the Stop TB partnership called for strengthening of diagnos-
tic services and highlighted the need for the development of rapid
diagnostics to ﬁght the tuberculosis pandemic. In 2011, WHO esti-
mated that approximately 630,000 (5.3%) of the 12 million TB
cases had multiple drug resistant (MDR)-TB, while more than 80
countries have reported cases of extremely drug-resistant (XDR)-
TB. Only a small fraction of reported cases (<20%) were correctly
diagnosed and even fewer were treated according to WHO stan-
dards. In response the WHO endorsed the Genotype® MTBDRplus
(version 1.0) line probe assay (LPA) in 2008 and theXpert®MTB/RIF
assay in 2010. But these tests only provide evidence for resistance
to isoniazid and/or rifampicin. There continues to be a critical need
for a more comprehensive convenient diagnostic technology. The
highly multiplexed LATE-PCR assay for M(X)DR-TB described here
was designed to meet that need.\
Our goal was to ﬁrmly establish that a highly multiplexed
Linear-After-the-Exponential (LATE) PCR single closed-tube assay
can simultaneously detect and distinguish multiple mutations in
multiple gene targets that are known to confer resistance to isoni-
azid, rifampicin, ethambutol, oﬂoxacin, amikacin, kanamycin and
capreomycin.
Methods & Materials: In this initial study, DNA from clini-
cal isolates with different rpoB, katG, embB, inhA promoter, gyrB,
gyrA and rrs genotypes were selected from a DNA bank housed at
Stellenbosch University. Each DNA samples was ampliﬁed and the
singled-strandedDNAproductswere scanned formutations at end-
point using the same mixture of Lights-On/Lights-Off Probes. The
resulting ﬂuorescent signatures were compared to that of H37Rv,
a pan-susceptible “wildtype” strain.
Results: Each clinical isolate harbouring a unique mutation had
its own, highly reproducible ﬂuorescent signature distinct from
that of H37Rv, as well as all other isolates with differentmutations.
Conclusion: This study achieved the intended transfer of the
Brandeis University technology to Stellenbosch University. This
study also demonstrates that this single tube multiplexed assay
can simultaneously distinguish the different mutations that confer
resistance to rifampicin, isoniazid, ethambutol, ﬂuoroquinolones,
aminoglycosides and ethionamide in less than three hours.
(Supported by NIH Grant R01 A1099532)
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Classiﬁcation of tuberculous meningitis using
Marais Criteria
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1 Universidad Iberoamericana Unibe, Santo
Domingo, Dominican Republic
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Domingo, Dominican Republic
Background: Tuberculous meningitis (TBM) diagnosis is dif-
ﬁcult, being the worst prognostic form of extrapulmonary
tuberculosis. Diagnostic delays contribute signiﬁcantly tomortality
and neurologic sequelae.
Methods&Materials:Weperformed anobservational, descrip-
tive and transversal study applying new consensus criteria for the
deﬁnition of Meningeal Tuberculosis diagnosis and British Medical
Research Council stage prognosis. In the study period, 68 patients
were identiﬁed for tuberculous meningitis, 40 were excluded, and
the ﬁnal sample consisted of 28 cases
Results: The diagnostic group “Possible” was the most common
with 35.7%, followed by Deﬁnite with 28.6%, Probable 21.4%, and
14.3% were excluded as Non-tuberculous meningitis in which an
alternative diagnosis was established or considered dual disease.
60.71% were less than 5 years of age. 78.6% were male. 80.77%
patients had symptoms for more than 5 days. 88.46% patients
had focal neurological deﬁcits. 64% patients showed alteration of
consciousness. 64.3%underwentneuroimaging,which50%demon-
strated hydrocephalus. 75% of patients were in Stage III of the
prognostic British Medical Research Council classiﬁcation. 7.1%
died.
Conclusion: Classiﬁcation of tuberculous meningitis allows
early diagnosis and treatment. Tuberculous meningitis manifesta-
tions vary and TBM is usually diagnosed when brain damage has
already occurred.
http://dx.doi.org/10.1016/j.ijid.2014.03.1202
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Detection of toxigenic Clostridium difﬁcile by
Loop-Mediated Isothermal Ampliﬁcation
(LAMP)
P. Jayaratne
St. Joseph’s Healthcare, Hamilton, ON, Canada
Background: Clostridium difﬁcile-associated disease (CDAD) is a
leading cause of nosocomial diarrhea in adults. Therefore, rapid and
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accurate reporting of toxigenic C. difﬁcile is essential for improv-
ing patient outcomes and minimizing hospital-acquired disease.
The PCR-based in-house and commercial methods available now
to detect toxigenic C. difﬁcile are expensive or require nucleic
acid puriﬁcation.We describe amultiplex real-time loop-mediated
isothermal ampliﬁcation method (LAMP) to detect toxigenic C. dif-
ﬁcile without DNA puriﬁcation and to presumptively identify the
NAP1 strain directly from diarrheal stools.
Methods & Materials: Five-hundred and eighteen stools sub-
mitted for routine PCR testing of C. difﬁcile was used. The DNA was
extracted by mixing and boiling 100l of 1:10 dilution of stools
with 100l of lysis solution for 15min. Twomicroliters of the clear
supernatant was used for LAMP reactions. LAMP method ampliﬁed
and detected tcdC, cdtA, and 
DNA (IC). Primers used for ampliﬁca-
tion were designed using Genbank and PrimerExplorer V4 (Eiken
Chemical Co., Ltd. Japan). DNA ampliﬁcation was done at 59 0C
for 60min using Rotorgene 6500 (Qiagen) and a standard LAMP
reaction. Ampliﬁcation was detected by displacement of a ﬂuores-
cent probe annealed to the quencher-labeled primer: Detection of
AmpliﬁcationusingReducedQuenching (DARQ). The limit of detec-
tion (LOD) was determined by using a C. difﬁcile negative stool
specimen spiked with known number of colony forming units of
C. difﬁcile ATCC43255.
Results: Out of 518 specimens 200 tested were positive and 307
were negative for tcdC by both methods. There were 11 discrepant
specimens that were all negative by LAMP but positive by PCR with
high CT values (>35). The test performance characteristics of LAMP
method as compared to the PCR was as follows: sensitivity, 95%;
speciﬁcity, 100%; NPV, 97%; PPV, 100%. The LOD was estimated to
be 750 genome equivalents. The presence of both tcdC and cdtA
presumptively identiﬁed 65 specimens to have the NAP1 strain by
both methods.
Conclusion: The turn-around-time for LAMP-DARQ was 90min
as compared to 3.5hours for the in-house PCR. The estimated cost
per test for LAMP-DARQ was Cdn $4.00 and 60% cheaper than the
PCR. The LAMP-DARQ is a cost-effective, sensitive, faster method
than PCR to detect toxigenic C. difﬁcile.
http://dx.doi.org/10.1016/j.ijid.2014.03.1203
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Cross-species multiplex microarray for
serological detection of ﬂavi-, phlebo- and
alphaviruses
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1 Erasmus Medical Center and Center for Infectious
Disease Control, Bilthoven, Netherlands
2 Center for Infectious Disease Control, Bilthoven,
Netherlands
3 GD, Animal Health Services, Deventer, Netherlands
4 Central Veterinary Institute of Wageningen
University Research, Lelystad, Netherlands
5 Colorado State University, Fort Collins, USA
Background: New animal and human diseases continue to
emerge across the world, inﬂuenced by human and animal pop-
ulation densities, climate and globalization in travel and trade.
Arboviruses form a speciﬁc group within these (re-)emerging
threats and, due to their vector-borne and zoonotic nature,
require extensive, complex and expensive surveillance and con-
trol schemes. They cause clinical diseases in both humans and
animals, ranging from life threatening meningoencephalomyelitis
and hemorrhagic fever to rash and crippling arthralgia. Diagnosis
is based mostly on serology, as viremia is often short-lived. Fur-
ther complicating diagnostics is the fact that clinical syndromes
and geographical distribution overlap, and antibodies cross-react
extensively within virus families in common serological tests. Our
objective is to be able to detect, diagnose and monitor clinically
signiﬁcant arboviruses simultaneously inmultiple species andwith
an approach easily adaptable to constantly changing demographics
and syndromes. Thereforewedevelop anovel cross-species protein
microarray for proﬁling of antibodies to six ﬂaviviruses (DENV1-4,
WNV, JEV, TBEV, USUV, YFV), three alphaviruses (CHIKV, ONNV,
SINV) and one phlebovirus (RVFV).
Methods & Materials: Target antigens were selected and spot-
ted onto nitrocellulose pads using a non-contact array spotter.
Serum samples fromhumans (180), horses (80), sheep (160), chick-
ens (10) and other bird species (15) with virologically and/or
serologically conﬁrmed arboviral infections and control sera of
non-exposed individuals were incubated in serial 2-fold dilutions
followed by incubation with a species speciﬁc IgG, IgM or IgY
speciﬁc Cy5-labeled conjugate. After quantifying signals using a
scanarray scanner, data were analyzed in ‘R’.
Results: Proﬁling of antibodies in human patients exposed
to ﬂaviviruses and alphaviruses showed highly discriminatory
patterns of reactivity with sensitivities and speciﬁcities ranging
from 87%-100%. Additionally, vaccinated individuals could be dis-
tinguished from non-vaccinated individuals. Initial results also
showed high sensitivity and speciﬁcity of 100% for sheep infected
with RVFV and horses infected with JEV, while WNV showed some
cross-reactivity with JEV and USUV antigens in horses. Further
testing is ongoing to determine the usefulness of this system for
multiple bird species.
